­

Howard Safran, MD, Director, The Brown University Oncology Group Professor of Medicine, The Warren Alpert Medical School of Brown University

  • Howard Safran, MD, director of the Brown University Oncology Research Group (BrUOG) and associate professor of medicine at the Warren Alpert Medical School of Brown University, is the principal investigator of the clinical trial evaluating ADXS-HPV in HPV-associated anal cancer.
    • Dr. Safran briefly presented the current treatment landscape for anal cancer, noting that 40% of patients will present with bulky and/or locally advanced disease and have a very high risk of recurrence following therapy with curative intent, including chemoradiation.
    • The BrUOG initiated a phase I/II study of ADXS-HPV administered prior to and following standard chemoradiation treatment of HPV-positive anal cancer. Ten of the planned 25 patients have been enrolled; Dr. Safran commented that all 10 enrolled patients had achieved a 6-month complete response and not one had experienced disease recurrence, with up to 2 years of follow-up.
    • These encouraging preliminary results with ADXS-HPV in anal cancer have prompted additional clinical trials, one of which is currently planned for the treatment of metastatic disease.